Anavex Life Sciences Stock Earnings Reports

Key points for investors: 1) Regulatory: Management expects the CHMP to adopt a negative opinion on the MAA for blacaramazine at its December meeting and intends to request a reexamination. The company completed a full GCP inspection and the manufacturing package passed EMA review. Initial contacts with the FDA on the Alzheimer program have begun. 2) Clinical data: Multiple peer-reviewed/publication updates reported — including prevention data in preclinical models, biomarker/autophagy mechanism work, and the AB-CLR (ABCEAR) precision-medicine analyses showing substantially reduced cognitive decline (ADAS-Cog13 differences growing through 144 weeks versus ADNI natural-history control, equating to ~17.8 months of time preserved). New genomic findings (COL24A1 and sigma-1 receptor wild-type subpopulations) define precision-medicine responders. 3) ANAVEX 3-71: Positive Phase 2 topline safety results in schizophrenia (well tolerated, no serious/severe TEAEs) with encouraging biomarker (GFAP) reductions and exploratory efficacy trends; company positions 3-71 for pivotal development across neuropsychiatric indications including depression in Alzheimer’s. 4) Financials: Cash was $102.6M as of Sept 30; management states current cash >$120M, no debt, cash runway >3 years at current burn. Q4 R&D was $7.3M (down YoY), G&A $3.5M, and net loss $9.8M ($0.11/share). 5) Corporate strategy: Management will pursue reexamination with EMA, continue FDA interactions, publish/ present additional data (including brain-atrophy correlations), and actively seek strategic partnerships/BD at upcoming conferences.